Adocia SA is looking to further apply its Biochaperone formulation technology to metabolic disorders, Olivier Soula, Adocia ...

Activating the glucagon-like peptide 1 receptor (GLP-1R) is the mechanism of action of most drugs currently used to treat ...

Preclinical results were recently presented from studies conducted by Fulcrum Therapeutics Inc. evaluating FTX-6274, a novel, ...

Mode Sensors AS received U.S. FDA 510(k) clearance for its Re:Balans hydration monitoring system. The wearable patch sensor ...

India’s Central Drugs Standard Control Organization (CDSCO) posted a draft guidance for medical device software, providing ...

Sustaining healthy weight loss is about so much more than cutting calories or injecting drugs, as many GLP-1 users are ...

During the first poster session of the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer ...

Adoptive cell therapy represents a major step forward in treating hematological cancers. Among its different approaches, chimeric antigen receptor natural killer (CAR-NK) cells are drawing growing ...

Inhibrx said the encouraging results in treating the rare, slow growing cancer that often begins in the bone, bolster its plans to file a BLA in the second quarter of 2026. The company’s stock (NASDAQ ...

Researchers at the University of California, Los Angeles (UCLA), have developed a new type of allogeneic immune cell therapy that demonstrated potent antitumor activity against triple-negative breast ...

Mutant KRAS is a well-known oncogenic driver and has remained undruggable for many decades. The development of pan-KRAS inhibitors that target a broad range of mutations is a promising approach to ...

Interline Therapeutics Inc. has identified new compounds receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of inflammatory bowel ...